Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001415889-25-008509 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-18 | 2025-03-14 | LYEL | Seely Lynn | Pres, CEO, Dir | P - Purchase | $0.61 | +175.0K | 712.5K | +33% | +$106.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | P | A | 175,000 | $0.61 | 712,500 | D | — | — | (F1) The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59980 to $0.62020, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range. |